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SUMMARY
Testicular cancer (TC) is currently the most common malignant solid tumour in Caucasian males aged 15–39 years. Epidemiologi-
cal evidence suggests that its onset may be due to an imbalance in the action of steroidal sex hormones and their receptors. A faulty
androgen receptor signalling pathway can, in fact, cause various male reproductive disorders. The androgen receptor (AR) gene has
two polymorphic segments consisting of CAG and GGC repeats. The length of CAG repeats has been shown to affect the regulation of
AR activity. In our study, we used fragment analysis to evaluate the AR gene repeats of 302 TC patients and 322 controls, to establish
if there is any association between repeat number and TC. This study of the largest Italian caseload investigated to date highlighted
three particularly significant aspects. First, a CAG repeat number of ≥25 may be considered a risk factor for the onset of TC, given its
greater frequency in patients in comparison with controls. This difference became significant for the non-seminoma group. Second,
men with CAG repeats below 21 or above 24 were found to have a, respectively, 50 and 76% higher risk of TC than those with CAG
21–24, suggesting that these too can be considered a risk factor for TC. Finally, stage II patients were more likely to have a CAG repeat
number <21 or >24 than stage I patients.
INTRODUCTION
Testicular cancer is currently the most common malignant
solid tumour in Caucasian males aged 15–39 years. Its incidence
varies by geographical area and may be up to three or four times
higher in northern Europe and New Zealand than in the global
population as a whole (Adami et al., 1994; Hemminki & Li, 2004;
Richiardi et al., 2004). In Scandinavian countries, the epidemio-
logical trends for testicular germ cell tumours (TGCTs) differ
greatly, despite their geographical proximity and social similari-
ties. In Denmark, the risk of TGCT is, in fact, five times higher
than in Finland, with Sweden having an intermediate risk.
Among TGCTs, seminoma alone accounts for about 50% of all
TC (Huyge et al., 2003). Various risk factors correlated with TC
have been known for many years, even though the main causes
remain obscure. The most important risk factors include familial
history of TC, previous TGCT and cryptorchidism (Forman et al.,
1992; Schnack et al., 2009). It has also been suggested that TGCT
associated with impaired spermatogenesis and other male
reproductive system abnormalities may form part of a larger
condition known as testicular dysgenesis syndrome (TDS) (Skak-
kebæk et al., 2001). Epidemiological evidence suggests that the
onset of TDS, including TGCT, may be due to an imbalance in
the action of steroidal sex hormones. Reduced androgen activity
as a function of oestrogen activity during male foetal develop-
ment would thus lead to the various reproductive abnormalities
typical of TDS (Martin et al., 2008). Because of androgen recep-
tor (AR) gene mutations, such patients have a high risk of devel-
oping malignant testicular tumours, as this gene is essential for
the correct development of the male phenotype and of sper-
matogenesis. The AR gene is located on the X chromosome at
Xq11-12 and has two polymorphic regions on exon 1, (CAGn)
CAA and (GGT)3GGG(GGT)2(GGC)n, known, respectively, as CAG
and GGN, where the first includes CAG repeats and the second
GGC repeats. The extreme variability of these repeats determines
the different lengths of the polyglutamine and polyglycine seg-
ments in the N-terminal transactivation domain. This seems to
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have a fundamental role in modulating AR function and thus
sensitivity. The number of CAG repeats has been shown to affect
the regulation of AR activity (Gao et al., 1996). In vitro and in
vivo studies have demonstrated that the more CAG repeats, the
weaker and looser the bond and thus the weaker the receptor’s
transactivating capacity (Chamberlain et al., 1994; Choong et al.,
1996; Buchanan et al., 2004). The two factors thus show an
inverse correlation, according to many authors, although a 2010
study (Nenonen et al., 2010) seems to contradict this, finding
instead that receptor activity is lower in both short and long
repeats than in those of an average length. In men, the number
of CAG repeats can vary from 8 to 37, with a mean of 20–22
depending on ethnic origin. African Americans have a lower
number of repeats than Caucasians, and a reduced risk of TGCT
(Schottenfeld et al., 1980; Edwards et al., 1992; Tut et al., 1997;
Kuhlenbaumer et al., 2001). In the last decade, some studies
have tried to establish if there is any association between CAG
and GGC repeat number and testicular tumours, but the results
appear contradictory (Rajpert-De Meyts et al., 2002; Giwercman
et al., 2004; Davis-Dao et al., 2011; V€astermark et al., 2011; Kris-
tiansen et al., 2012). Some of these studies also found other AR
mutations, such as single-nucleotide polymorphism (SNP), only
in those patients with TC (Garolla et al., 2005; V€astermark et al.,
2011).
In our study, we analysed CAG and GGC repeats in a large
caseload of TC patients to attempt to establish if there is any
association between the two. We were particularly interested in
investigating any correlation with the histotype and stage, which
despite its potential importance has been generally neglected in
the literature. This approach could help clarify the role played by
AR in various cancer types and stages, as well as facilitating
understanding of and simplifying a topic which is still highly
controversial, often because of the use of caseloads too small to
have any clinical significance.
MATERIALS ANDMETHODS
Subjects
The study was approved by our University Hospital Ethics
Committee. This case-controlled study recruited 302 TC patients
(seminoma and non-seminoma) attending the Seminology labo-
ratory sperm bank at the University of Rome “La Sapienza”
Department of Experimental Medicine - Medical Pathophysiol-
ogy Section for cryobanking of semen. All patients were studied
after removal of the affected testicle and before the start of
chemo- or radiotherapy. The control group consisted of 322 can-
cer-free men, recruited in the same Department, who were
undergoing a preventive andrological investigation comprising
medical history, andrological examination, semen analysis, hor-
mone study and testis ultrasound. These subjects were chosen
on the basis of the absence of any clinical signs resulting from
this investigation, namely: no family history of TC, normal scro-
tal palpation and ultrasound, normozoospermia and hormone
profile in the normal range.
Genotyping
A sample of peripheral venous blood was taken from all
patients and controls for molecular evaluation of the length of
the polyglutamine and polyglycine segments of the AR gene
(CAG and GGC repeats).
Genomic DNA was extracted from peripheral blood leucocytes
using the Wizard Genomic extraction kit (Promega Corporation
Madison, WI, USA). Concentration and purity were evaluated by
Nanodrop ND 1000 (Thermo Fisher Scientific, Waltham, MA,
USA).
The length of the polymorphic fragments and thus the number
of CAG and GGC repeats were analysed by primers flanking the
triplet repeat regions.
The amplification reactions for both CAG and GGC repeats
were carried out in 25 lL containing 0.5 ng of genomic DNA,
0.8 lM of each primer and 12.5 lL of Ampli Aaq Gold 360 Master
Mix (Applied Biosystems, Carlsbad, CA, USA). The CAG amplifi-
cation protocol consisted of 10 min at 95 °C followed by 30
cycles of 45 sec at 94 °C, 30 sec at 59 °C and 1 min at 72 °C.
GGC amplification involved 5 min at 95 °C followed by 30 cycles
of 40 sec at 95 °C, 30 sec at 55 °C and 30 sec at 72 °C, with a
final extension step at 72 °C for 15 min.
Capillary electrophoresis was carried out using 10 lL of a reac-
tion mixture consisting of 2.5 lL of PCR product (for both CAG
and GGC), 0.3 lL of Genescan LIZ 600 (Applied Biosystems) and
7.7 lL of formamide. Samples were first denatured for 5 min at
95 °C and then loaded into a 3500 Genetic Analyser (Applied
Biosystems). The forward primer for CAG and GGC had been
fluorescently labelled with FAM at 50 to enable the fragment to
be seen during electrophoresis (fragment analysis). The follow-
ing primers were used:
CAG – forward: FAM-TCCAGAATCTGTTCCAGAGCGTGC,
reverse: GCTGTGAAGGTTGCTGTTCCTCAT; GGC – forward:
FAM-GTGTGTAGTCCACGCCACTTCAGCGAAAGG, reverse: GGA
AAGCGACTTCACCGCACCTGATGTGTG.
Raw data from the capillary electrophoresis were analysed by
Gene Mapper Analysis (Applied Biosystems).
Statistical analysis
The statistical analysis was performed using Statistical Pack-
age for the Social Sciences (SPSS) 17.0 (SPSS Inc., Chicago, IL,
USA). The inter-group comparisons of the CAG and GGC
repeats were performed using the Mann–Whitney test. All statis-
tical tests were two-sided. A p-values of <0.05 were considered
statistically significant. Logistic regression models were used to
derive the odds ratio (OR) of TC according to the number of
CAG and GGC repeats.
The CAG repeat numbers were divided into CAG = 21–24, set
as the reference, CAG <21 and CAG >24. The reference corre-
sponded to the median quartiles ranging from the lower 25th
(CAG = 21) to the upper 75th (CAG = 24) percentile of the con-
trol group, i.e. the cut-points delimiting the shortest and longest
stretches of our control sample.
We identified the cut-points on the basis of CAG number distribution
in the control group (322 patients), taking inspiration fromNenonen’s in
vitro study. This study showed that extremely long and short CAG
repeats (16, 28 CAG) have lower AR activity than does the median CAG
length (22 CAG) (Nenonen et al., 2010).
We also conducted a sensitivity analysis based on different
cut-points and excluding the variable stage I, to evaluate any
change to the magnitude of the association between CAG repeat
length and TC.
Binary logistic regression was applied with presence of TC
(yes/no) as the dependent variable. The proportion of subjects
with long CAG (≥25) was determined for the two groups
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(seminomas, non-seminomas) and controls and compared by
the use of Fisher’s exact test. Analyses were also conducted with
respect to stage of the disease, excluding advanced stage
because of the low number of subjects (n = 24) affected.
RESULTS
Of the 302 TC patients included in the study, 166 had been
diagnosed with seminoma and 136 non-seminoma. Patients
were also classified on the basis of clinical stage (TNM classifica-
tion), with 153 patients in stage I, 125 in stage II and 24 in
advanced stage.
The mean age SD at the time of diagnosis was
30.85  6.59 years (range 15–55 years) for the TC group as a
whole and 32.08  6.27 (15–48) for the control group. This dif-
ference was statistically significant (p = 0.018). There was no
appreciable difference in the age at diagnosis for seminoma
cases and controls, whereas non-seminoma patients were signif-
icantly younger than the controls (p <0.05). The CAG and GGC
repeat number distribution is shown in Fig. 1.
The means and standard deviations for CAG and GGC repeat
number in the TC patients and controls are given in Table 1. The
mean number of CAG repeats was 22.25  3.12 and
22.26  2.75 for patients and controls respectively; this differ-
ence was not significant. The median was 22 for both patients
and controls. There was no appreciable difference in the mean
number of GGC repeats between patients (17.06  2.02) and
controls (17.08  1.68). The median number of GGC repeats was
17 for both patients and controls.
Comparison of the TC patients and controls by the Mann–
Whitney test did not reveal any statistically significant difference
in either of the repeats for the TC group as a whole or for the var-
ious histotypes (seminomas, non-seminomas) compared against
each other and against the control group. The proportion of
males with CAG repeat number 25 or over was significantly
higher in TC patients (26.2%) than in controls (18.6%)
(p = 0.027) (Fig. 2). There was no significant difference in mean
CAG repeat number between the TC patients and the controls
(equal variance, p >0.05). However, when the CAG repeat num-
ber was divided into three subgroups (<21, 21–24 and >24) for
the stratified analysis, the OR for TC patients was 50% higher
[95% confidence interval (CI): 1.02–2.20] for CAG repeats <21
and 76% higher (95% CI: 1.18–2.63) for CAG repeats >24 with
respect to the reference group of controls. This difference was
more significant in subjects with stage II disease at the time of
diagnosis (Table 2). The OR for the presence of disease stage II,
regardless of the histotype, was thus 2.00 (95% CI: 1.22–3.26) for
CAG repeats <21 and 1.92 (95% CI: 1.13–3.26) for CAG repeats
>24, compared with a CAG repeat number 21–24 (Table 2).
Advanced stage was excluded from the analysis because of the
low number of subjects (n = 24) concerned. These results were
confirmed by a sensitivity analysis excluding stage I patients,
which showed that the direction and magnitude of the associa-
tion between CAG repeat length and TC were amplified at stage
II (data not shown).
We also examined the joint association of CAG and GGC
repeats in relation to the risk of TC in these two categories.
The OR value was significantly increased (OR: 2.20; 95%
Figure 1 Bar charts displaying distributions of the CAG and GGC repeat number in testicular cancer patients (light bars) and controls (dark bars).
Table 1 Means and standard deviations of CAG and GGC repeat number
in testicular cancer patients and controls
Seminomas Non-
seminomas
All testicular
cancer
Controls
No. of
patients
166 136 302 322
CAG
repeat
number
22.17  3.27 22.36  2.93 22.25  3.12 22.26  2.75
GGC
repeat
number
17.10  2.00 17.01  2.05 17.06  2.02 17.08  1.68
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CI: 1.13–4.28) in the haplotype, in which both CAG and GGC
repeat numbers alleles were high (CAG >24; GGC >18) compared
to the reference group (CAG 21–24; GGC ≤ 17) (Table 3). When
analysing cancer stage II only, the OR for TC was 165% higher
[95% confidence interval (CI): 1.12–6.30] for men in which both
the alleles were long (CAG >24; GGC >18) and 139% higher (95%
CI: 1.28–4.46) for men with short repeats (CAG <21, GGC ≤17)
than for the reference group (Table 3).
DISCUSSION
Testicular cancer is a very common disease whose incidence
worldwide has been rising, especially in recent decades. Testicu-
lar germ cell tumours make up 95% of all TCs and are the most
common solid tumour in men aged 15–39 years (Devesa et al.,
1995; Huyge et al., 2003). Although there has been enormous
progress in the clinical treatment of TC and preservation of fer-
tility through sperm banking in recent years, the main causes of
this disease remain still unclear. However, important risk factors
include familial history, lifestyle, diet, environmental conditions
and genetic susceptibility (Skakkebæk et al., 2001; Krausz & Loo-
ijenga, 2008; Giannandrea et al., 2011, 2013). The development
of TC is postulated to be due to endocrine disruption, particu-
larly abnormalities in the action of gonadotropins and steroidal
sex hormones (Rajpert-De Meyts & Skakkebæk, 1993). Men with
androgen insensitivity syndrome caused by AR gene mutations
have a higher risk of developing TC. There is some evidence of
an inverse correlation between AR gene CAG repeat number var-
iability and the receptor’s transactivation efficiency. Irvine sug-
gested that a longer CAG repeat region might reduce the
receptor’s transactivation activity (Irvine et al., 2000).
Androgen receptor gene abnormalities are also common in
other disorders, such as cryptorchidism and impaired spermato-
genesis. Analysis of the number of CAG repeats in infertile men
has produced contrasting results (Giwercman et al., 1998; Patri-
zio & Leonard, 2001; Ferlin et al., 2004; Milatiner et al., 2004).
Many authors have worked to try to understand if reduced
androgen sensitivity because of point mutations, or more often
caused by an excessively long CAG repeat segment, might lead
to the development of testicular dysgenesis and consequently
increase susceptibility to TC. Rajpert-De-Meyts et al. (2002)
analysed CAG repeats in a Danish population of 102 TC patients
and 110 controls. No statistically significant differences were
found in the distribution of CAG repeat number between the
two groups, analysed by both histotype and stage. Giwercman
et al. investigated the correlation between CAG and GGC repeats
in a population from Malmo consisting of 83 TGCT patients and
220 controls. No statistically significant differences in CAG or
GGC repeat number were seen between TGCT patients and the
control group. However, it is interesting to note that the number
of men with CAG repeat number >25 was significantly lower in
seminoma patients and in seminoma + non-seminoma patients
than in the controls. Longer CAG repeat numbers were found in
patients with more advanced cancer at the time of diagnosis,
although this was not statistically significant. This study seems
to suggest, therefore, that CAG repeats may be correlated with
the presence or absence of metastasis on diagnosis, where a
longer repeat number would indicate a higher chance of metas-
tasis. This was the first study that demonstrated a correlation
between AR CAG repeats, TGCT histology and disease progres-
sion, albeit in a limited caseload (Giwercman et al., 2004).
Garolla et al. (2005) analysed 123 TC patients, all at stage 1 at
the time of study, against a control group of 300 fertile men stud-
ied for AR mutations, of whom 115 were selected for the study of
CAG and GGC repeats. There were no differences in the number
of CAG and GGC repeats between patients and controls. This
study did not confirm the differences found between cancer his-
totypes or the greater frequency of CAG >25 in patients vs con-
trols in Giwercman et al. (2004) study. Instead, it seemed to
corroborate the results of Rajpert-De Meyts et al. (2002) Danish
study. However, when Garolla et al. considered both CAG and
GGC repeats together, they found that the distribution of CAG/
GGC = 20/17 was significantly higher in TC patients (8.1%) than
in controls (1.7) (p < 0.05). This study also found two single
nucleotide point mutations involving amino acid substitution:
proline to serine at position 390 P390S and alanine to threonine
at position 297 (A297T), as well as a trinucleotide deletion of
leucine at position 57 (Del L57). All three of these mutations
were only found in seminoma patients, suggesting their involve-
ment in this specific histotype.
A Scandinavian study examined 367 Danish and Swedish
TGCT patients, with 214 Swedish men as the control group. CAG
Table 2 Risk of testicular cancer in relation to CAG and GGC repeat
number
No. of CAG repeats No. of GGC repeats
<21 21–24 >24 ≤17 >17
Controls
(322 pts)
74 188 60 206 116
All TC
(302 pts)
83 140 79 182 120
OR 1.50 1.0 1.76 1.0 1.17
95% CI 1.02–2.20 Reference 1.18–2.63 Reference 0.84–1.61
p value 0.036 0.005 0.34
Stage I
(153 pts)
35 76 42 91 62
OR 1.17 1.0 1.73 1.0 1.21
95% CI 0.72–1.89 Reference 1.07–2.78 Reference 0.81–1.79
p value 0.52 0.024 0.34
Stage II
(125 pts)
41 52 32 77 48
OR 2.00 1.0 1.92 1.0 1.10
95% CI 1.22–3.26 Reference 1.13–3.26 Reference 0.72–1.69
p value 0.005 0.015 0.64
TC cases Controls
26.2% 18.6%
73.8% 81.4%
C
A
G
 <
25
C
A
G
 ≥
25
Figure 2 Percentage of males with CAG lengths ≥25 or <25 in TC patients
and controls.
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and GGC repeat number were evaluated, along with 11 AR SNPs.
One of these, genotype G of the non-coding SNP rs12014709,
was found in 10% of TGCT cases and 5.1% of controls, and was
thus associated with the TGCT group. None of the other SNPs or
CAG repeats was significantly associated with an increased or
reduced risk of developing TGCT. This study also found that a
GGN repeat number <23, consisting of <17 GGC repeats, was
correlated with an increased risk of developing non-seminoma-
tous TGCT and with an increased risk of metastasis (V€astermark
et al., 2011) .
In 2012, Kristiansen et al. investigated the correlation between
CAG and GGN repeats and TC in a Norwegian population. The
study involved 651 TC patients and 313 controls. No statistically
significant differences were seen in the number of CAG and
GGN repeats between patients and controls, even when analysed
by histotype (Kristiansen et al., 2012). In addition, they could
not confirm Giwercman’s finding that CAG >25 was more com-
mon in patients with non-seminomatous tumours (Giwercman
et al., 2004).
In our study, there was no statistically significant difference in
average CAG and GGC repeat number between the TC patients
and controls. There was a larger variability of CAG than GGC
repeats in both patients and controls, especially among the rare
alleles. When stratified, men with CAG repeats below 21 or above
24 were found to have a, respectively, 50 and 76% higher risk of
TC than those with CAG 21–24. In other words, the risk of devel-
oping TC would seem to be lower for men with a CAG repeat
number between 21 and 24.
This finding of a non-linear relationship between CAG repeat
number and the risk of TC may be comparable with similar
results showing a U-shaped correlation between CAG repeat
number and total sperm number. Such an association was in
fact shown in vitro and confirmed in human studies which
found that men with CAG repeats below 22 or above 23 have an
approximately 20% higher risk of infertility than those with CAG
22 or 23 (Nenonen et al., 2011). It has been hypothesized that as
91–99% of the CAG alleles in the general population have a
length between 16 and 29, repeats outside this critical range
could be a more important mediator of reproductive diseases
such as male infertility (Buchanan et al., 2004). In this context,
our results support the suggestion that normal AR function is
sustained over a critical but limited range of CAG repeat num-
bers. A similar finding has also been reported in vitro in relation
to GGC repeats. The most common GGN segment (17 GGC
repeats) was shown to have the highest transactivating capacity
(Lundin et al., 2007) and was also associated with the lowest risk
of male genital malformations (Aschim et al., 2004) linked to
reduced androgen activity (Lundin et al., 2006).
Previous studies showed that men with CAG repeats above 25
were less androgen sensitive than those with shorter segments.
In our study, the proportion of subjects with long CAG repeats
(≥25) was higher in TC cases than controls. This difference
became significant for the non-seminoma group with respect to
controls. Similar results were found by Giwercman et al. (2004),
suggesting that CAG repeats >25 were more common in patients
with non-seminoma. However, other studies did not find such
differences between the histological groups (Kristiansen et al.,
2012).
Previous studies have correlated CAG repeats with clinical
stage of TC, with some finding that CAG repeat number was
higher if the tumour was advanced at diagnosis (Giwercman
et al., 2004). In our study, there was a statistically significant dif-
ference in CAG but not GGC repeats according to the stage of
the disease, with the longest or shortest repeats found among
patients with stage II disease at the time of diagnosis. Analysing
stage II, the OR of TC was higher for men in which the alleles
were both long (CAG >24; GGC >18) or both short (CAG <21,
GGC ≤17). This trend was obvious for both histotypes under
study (seminomas, non-seminoma) vs controls.
In conclusion, this study of the largest Italian caseload investi-
gated to date has highlighted three particularly significant
aspects. First, a CAG repeat number of ≥25 may be considered a
risk factor for the onset of TC, given its greater frequency in
patients in comparison with the controls. This is of considerable
scientific and oncological interest, although it is difficult to
understand what biological mechanism might be responsible. It
Table 3 Joint association of CAG and GGC repeats in relation to the risk of testicular cancer
Combined CAG and GGC repeats <21, ≤17 >24, ≤17 21–24, ≤17 21–24, >18 <21, >18 >24, >18
Controls (322 pts) 48 43 115 73 26 17
TC cases (302 pts) 45 51 86 54 38 28
OR 1.25 1.58 1.0 0.98 1.95 2.20
95% CI 0.76–2.05 0.96–2.59 Reference 0.63–1.55 1.10–3.46 1.13–4.28
p value 0.36 0.06 0.96 0.02 0.02
Seminomas (166 pts) 25 22 50 30 22 17
OR 2.32 2.02 1.0 1.43 2.14 2.46
95% CI 1.28–4.19 1.08–3.79 Reference 0.80–2.54 1.03–4.46 1.06–5.66
p value 0.005 0.027 0.22 0.041 0.034
Non-seminomas (136 pts) 20 29 36 24 16 11
OR 1.33 2.15 1.0 1.05 1.96 2.06
95% CI 0.70–2.52 1.18–3.93 Reference 0.58–1.90 0.95–4.06 0.88–4.81
p value 0.38 0.012 0.87 0.06 0.092
Stage I (153 pts) 13 26 52 24 22 16
OR 0.59 1.33 1.0 0.72 1.87 2.08
95% CI 0.29–1.20 0.74–2.40 Reference 0.41–1.28 0.97–3.60 0.97–4.43
p value 0.14 0.33 0.26 0.061 0.05
Stage II (125 pts) 28 21 28 24 13 11
OR 2.39 2.00 1.0 1.35 2.05 2.65
95% CI 1.28–4.46 1.03–3.90 Reference 0.72–2.50 0.93–4.49 1.12–6.30
p value 0.006 0.040 0.34 0.072 0.027
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is possible that a greater CAG repeat number and consequent
reduced efficiency of the transactivation domain leads to a
diminished AR capacity to recognize and bind androgens, to
such an extent as to make them incapable of functioning cor-
rectly and result in a higher concentration of free hormones.
These two factors might thus play a part in the onset of TC.
Second, CAG repeats <21 and >24 are significantly associated
with TC, suggesting that they can be considered a risk factor for
the onset of this disease. The least risk is thus seen with CAG
repeat numbers between 21 and 24, which are the most common
in the general population, thus confirming in vitro findings.
Finally, stage II patients were more likely to have a CAG repeat
number <21 or >24 than stage I patients. All these aspects lead
us back to the crucial role played by the length of the polymor-
phic segment in androgen receptor function; a change in the
number of repeats can lead to various disorders and, above all, is
a risk factor for TC that should not be neglected. However, we
believe that comparative studies of groups of single ethnic ori-
gins are in any case necessary, given the highly variable distribu-
tion of these polymorphisms in different populations worldwide.
This will enable further understanding of the role of the AR gene
and polymorphism frequency in the onset of TC in patients of
different ethnic origins.
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